These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Interindividual variability in sensitivity to warfarin--Nature or nurture? Loebstein R; Yonath H; Peleg D; Almog S; Rotenberg M; Lubetsky A; Roitelman J; Harats D; Halkin H; Ezra D Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010 [TBL] [Abstract][Full Text] [Related]
5. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971 [TBL] [Abstract][Full Text] [Related]
6. Overview of pharmacogenetics in anticoagulation therapy. Hill CE; Duncan A Clin Lab Med; 2008 Dec; 28(4):513-24. PubMed ID: 19059059 [TBL] [Abstract][Full Text] [Related]
7. Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. Cavallari LH; Shin J; Perera MA Pharmacotherapy; 2011 Dec; 31(12):1192-207. PubMed ID: 22122181 [TBL] [Abstract][Full Text] [Related]
8. Warfarin sensitivity and genetic polymorphisms: should pharmacokinetic screening be part of anticoagulant dosing decisions? Baglin TP Clin Adv Hematol Oncol; 2003 Nov; 1(11):656-7. PubMed ID: 16258463 [No Abstract] [Full Text] [Related]
9. Is personalized medicine a dream or a reality? Morse BL; Kim RB Crit Rev Clin Lab Sci; 2015 Feb; 52(1):1-11. PubMed ID: 25181036 [TBL] [Abstract][Full Text] [Related]
10. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Herman D; Locatelli I; Grabnar I; Peternel P; Stegnar M; Mrhar A; Breskvar K; Dolzan V Pharmacogenomics J; 2005; 5(3):193-202. PubMed ID: 15824753 [TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of drug metabolising enzymes: importance for personalised medicine. Oscarson M Clin Chem Lab Med; 2003 Apr; 41(4):573-80. PubMed ID: 12747605 [TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 polymorphisms and drug-induced interstitial lung disease. Schwaiblmair M; Behr W; Foerg W; Berghaus T Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1547-60. PubMed ID: 22070131 [TBL] [Abstract][Full Text] [Related]
15. Cancer pharmacogenomics: international trends. Yamayoshi Y; Iida E; Tanigawara Y Int J Clin Oncol; 2005 Feb; 10(1):5-13. PubMed ID: 15729594 [TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics in drug regulation: promise, potential and pitfalls. Shah RR Philos Trans R Soc Lond B Biol Sci; 2005 Aug; 360(1460):1617-38. PubMed ID: 16096112 [TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics in Oral Antithrombotic Therapy. Maier CL; Duncan A; Hill CE Clin Lab Med; 2016 Sep; 36(3):461-72. PubMed ID: 27514462 [TBL] [Abstract][Full Text] [Related]
18. [Challenge in genome-wide association study for establishment of personalized medicine: focusing on the pharmacogenomics of warfarin and carbamazepine]. Mushiroda T Rinsho Byori; 2013 May; 61(5):422-7. PubMed ID: 23947182 [TBL] [Abstract][Full Text] [Related]
19. Warfarin dose prediction in children using pharmacogenetics information. Biss T; Hamberg AK; Avery P; Wadelius M; Kamali F Br J Haematol; 2012 Oct; 159(1):106-9. PubMed ID: 22804567 [No Abstract] [Full Text] [Related]